The French pharmaceutical company Sanofi is under increasing competition from generic manufacturers as profits dropped in the 3rd quarter of 2012. Between July and September, profits of Sanofi fell by almost a quarter: net income fell from July through September by about 23 percent to EUR 1.6 billion. However, the Paris-based company pointed out the cost of the Group’s restructuring and amortisation resulting in a decline in profits of 7.4 percent to EUR 2.2 billion.
The fourth largest pharmaceutical company in the world achieved double-digit increases in revenues thanks to diabetes drug Lantus and the continued growth in emerging markets sales increased by 3.3 percent to 9.04 billion Euros.
[ilink url=“http://en.sanofi.com/Images/31312_20121025_Q3_results_2012_en.pdf“] Link zur Quelle (Sanofi)[/ilink]